Received 30 December 2020 Revised 18 February 2021 Accepted 26 February 2021 DOI 101111obr13248 O B E S I T Y C O M O R B I D I T Y E T I O L O G Y A N D P A T H O P H Y S I O L O G Y Neutral sphingomyelinase2 cardiometabolic diseases Sardar Sindhu1 S R Murthy Madiraju23 Yat Hei Leung23 Hossein Arefanian4 Fahd AlMulla5 Rasheed Ahmad4 Marc Prentki23 Summary Sphingolipids particular ceramides play vital role pathophysiological processes linked metabolic syndrome implications development insulin resis tance pancreatic ßcell dysfunction type 2 diabetes atherosclerosis inflammation nonalcoholic steatohepatitis cancer Ceramides produced hydrolysis sphingomyelin catalyzed different sphingomyelinases including neutral sphingomyelinase 2 nSMase2 dysregulation appears underlie inflammationrelated pathologies In review discuss current knowledge biochemistry nSMase2 ceramide production regulation inflammatory cytokines particular reference cardiometabolic diseases nSMase2 contribution pathogenic processes appears involve cyclical feed forward interaction proinflammatory cytokines TNFα IL1ß activate nSMase2 production ceramides turn triggers synthesis release inflammatory cytokines We elaborate pathogenic interactions molecular level discuss potential therapeutic benefits inhibiting nSMase2 inflammationdriven cardiometabolic diseases K E Y W O R D S cardiometabolic diseases ceramide nSMase2 sphingolipid 1Animal Imaging core facility Dasman Diabetes Institute Dasman Kuwait 2Departments Nutrition Biochemistry Molecular Medicine University Montreal Montréal Quebec Canada 3Centre Recherche du Centre Hospitalier lUniversité Montréal CRCHUM Montreal Diabetes Research Center Montréal Quebec Canada 4Immunology Microbiology Department Dasman Diabetes Institute Dasman Kuwait 5Department Genetics Bioinformatics Dasman Diabetes Institute Dasman Kuwait Correspondence Rasheed Ahmad PhD Immunology Microbiology Department Dasman Diabetes Institute Dasman 15462 Kuwait Email rasheedahmaddasmaninstituteorg Marc Prentki PhD Professor Nutrition Biochemistry Molecular Medicine Université Montréal Director Montreal Diabetes Research Center CRCHUM Room R08412 Tour Viger 900 rue Saint Denis Montreal QC H2X 0A9 Canada Email marcprentkiumontrealca Funding information Canadian Institutes Health Research Montreal Medical InternationalDasman Diabetes Institute Abbreviations aSMase acid sphingomyelinase bSMase basic sphingomyelinase C1P ceramide1 phosphate CAT Cterminal catalytic domain DES dihydroceramide desaturase EED embryonic ectodermal development ER endoplasmic reticulum FAN factor associated nSMase GSH glutathione GSK3β glycogen synthase kinase IFNγ interferonγ IL1β interleukin 1β JNK cJun Nterminal kinase JX juxtamembrane LDL lowdensity lipoprotein MCP1 Monocyte Chemoattractant Protein1 NAFLD nonalcoholic fatty liver disease NASH nonalcoholic steatohepatitis NO nitric oxide nSMase2 neutral sphingomyelinase 2 NTD Nterminal domain OxLDL oxidized lowdensity lipoprotein PBMC peripheral blood mononuclear cells PP2A protein phosphatase2A ROS reactive oxygen species S1P sphingosine1phosphate SMase sphingomyelinase sSMase secretory sphingomyelinase T2D type 2 diabetes TLR tolllike receptor TNFR1 TNFα receptor TNFα tumor necrosis factorα ZDF Zucker diabetic fatty Sardar Sindhu Yat Hei Leung equally contributed work This open access article terms Creative Commons AttributionNonCommercialNoDerivs License permits use distribution medium provided original work properly cited use noncommercial modifications adaptations 2021 The Authors Obesity Reviews published John Wiley Sons Ltd behalf World Obesity Federation Obesity Reviews 202122e13248 httpsdoiorg101111obr13248 wileyonlinelibrarycomjournalobr 1 16 2 16 SINDHU ET AL 1 I N T RO DU CT I O N Sphingolipids components cellular membranes participate structural signaling pathways regulate cellu S P H I N G O LI P I D S 2 S P H I N G O M Y E L I N A S E S A N D CE R A M I D E S I N B R I E F lar functions By regulating pathways inflammation apoptosis 21 Mammalian sphingolipid metabolism proliferation sphingolipids serve bioactive molecules play major role pathophysiological mechanisms cardiometabolic Sphingolipids class lipids contain sphingoid base mainly cancer diseases type2 diabetes T2D atherosclerosis lung disease lysosomal storage disorders18 The knowledge signaling functions sphingolipids expanded considerably past decade expanded C18 backbone discovered brain extracts named enigmatic disposition56 mythological sphinx Sphingolipid metabolism consists intertwined network meta bolic pathways grouped key modules15758 diverse functions ceramides biological processes Ceramides 1 In endoplasmic reticulum ER central hub sphingolipid synthetized novo serine palmitoylCoA hydro metabolism novo biogenesis ceramides takes place In lysis ceramide1phosphate sphingosine involving ceramide process palmitoylCoA serine condensed produce synthase hydrolysis glucosylceramide action 3ketodihydrosphingosine subsequently dihydrosphingosine sphingomyelinases SMases family enzymes hydrolyze dihydroceramide eventually ceramide formed 2 Ceramide membrane lipid sphingomyelin generate phosphocholine ceramide910 SMasederived ceramides implicated signaling cell growth differentiation senescence apopto transported ER Golgi apparatus converted complex sphingolipids sphingomyelin glycosphingolipids59 3 In plasma membrane ceramide sis pathological inflammation insulin resistance diabetes converted bioactive molecules including ceramide1 phos atherosclerosis oxidative stress neurodegenerative disorders events1119 SMases classified families based pH optima metal ion requirement activity Their charac teristics roles briefly described separate section nSMase activity reported Schneider Kennedy fibroblasts patients NiemannPick disease20 It later characterized predominant membranebound enzyme crude extracts human gray matter21 Four nSMases nSMase2 described nSMase1 mitochondria associated nSMase22 All require neutral pH divalent cations MgMn hydrolysis phosphocholinehead group sphingomyelin generate ceramide23 nSMases nSMase3 nSMase3 phate C1P sphingomyelin sphingosine1phosphate S1P sphingosine57 4 Ceramide regeneration hydrolysis complex sphingolipids like sphingomyelin glycosphingolipids helps maintenance sphingolipid homeostasis60 Elevated novo biosynthesis ceramide ER results accumulation ER stress Reduced hydrolysis complex sphingolipids offsets homeo stasis leads excessive sphingolipid storage Ceramide sphingosine excess proapoptotic cause cell dediffer entiation senescence apoptosis growth arrest On hand C1P S1P prosurvival molecules involved angiogene sis proliferation migration transformation inflammation6164 Overall sequestration metabolic steps different subcellu lar compartments ensures organized orchestration complex DNaseI type catalytic core suggesting common mechanism enzymes sphingomyelin catalysis24 The roles sphingolipids membrane biology cell func tion dysregulation promote disease pathogenesis investigated isoform nSMase2 655 amino acid long 71 kDa Figure 1 protein localized plasma membrane Golgi apparatus cell types222527 It implicated diverse functions particular cell differentiation growth arrest1028 postnatal growth bone development2930 cell cycle31 cell adhesion migration proliferation32 senescence33 cell death apoptosis3435 autophagy36 exosome release3738 inflammatory immune responses283941 nSMase2 appears involved patho genesis diseases cancer4243 neurological age related neurodegenerative diseases amyotrophic lateral sclerosis Alzheimers disease Parkinsons disease4445 pulmonary4647 circulatory4750 cardiometabolic diseases5155 In present review focus recent development 22 Ceramide metabolism There characteristic pathways ceramide formation including 1 ceramide release sphingomyelin hydrolysis cell membrane review6566 pathway nSMase2 discussed 2 novo synthesis ER initiated serine palmitoyltransferasemediated conversion serine palmitoylCoA 3ketodihydrosphinganine subsequently yielding dihydroceramide converted dihydroceramide desaturase DES ceramide576067 3 salvage pathway knowledge role nSMase2 pathophysiology complex sphingolipids degraded ceramide metabolic syndromerelated disorders complications obe insulin resistance metabolic inflammation βcell dysfunction sity T2D nonalcoholic fatty liver disease NAFLD nonalcoholic enzymes present acidic lysosomes Then acid ceramidase verts ceramide sphingosine reenters cytosol recycled ceramide action ceramide synthase6869 steatohepatitis NASH atherosclerosis heart failure Figure 1 SINDHU ET AL 3 16 F I G U R E 1 Signaling cascade ceramides production pathogenesis metabolic disorders Ceramides synthesized novo palmitoylCoA sphingomyelin SMases sphingosine ceramide synthase ceramide1phosphate C1P phosphatase Accumulation ceramides causes oxidative stress activation different protein kinases leads mitochondrial dysfunction apoptosis insulin resistance inflammation These processes contribute pathogenesis metabolic diseases CVD cardiovascular diseases Ins Res insulin resistance NAFLD nonalcoholic fatty liver disease T2D type 2 diabetes Sphingomyelinase family members 23 roles N S M A S E 2 BI O C H E M I S T R Y A N D 3 RE G UL A TION The classes sphingomyelinases general character 31 Tissue distribution cellular localization istics 1 Acid sphingomyelinases aSMases optimum activity pH 5 localized lysosomes relocate outer leaflet plasma membrane7071 They play role cellular responses stress proliferation differentiation cell death7273 2 Secretory sphingomyelinases sSMases share com The nSMases discovered 1967 Schneider Kennedy20 Only decades purification cloning characteriza tion mammalian nSMase1 reported rat88 bovine89 brain However significant sphingomyelinase activity mon protein precursor aSMases different protein present removal nSMase1 activity brain homoge trafficking fate targeted Golgi secretory pathway These enzymes function best acidic pH require Zn2 activity7476 3 Mg2dependent neutral sphingomyelinases nSMases ER Golgi apparatus7077 inner plasma membranes7880 Their optimal pH 7 requires Mg2Mn2 tumor necrosis factorα TNFα oxidized lowdensity lipoproteins OxLDL81 These enzymes play role stressinduced cell death82 4 Mg2independent neutral sphingomyelinases identified growth factors activated leaflet nates soon led identification second nSMase named nSMase290 The nSMase isoforms differ tissue dis tribution expression nSMase1 ubiquitous nSMase2 highly expressed brain expression low bone liver spleen299092 nSMase2 originally shown localized subcompartment Golgi apparatus91 Then shown high cellular density enzyme translocated inner leaflet plasma membrane order contact lipid substrate9394 Figure 2 cytosol human leukemia cell line HL60 rabbit skeletal muscle optimal activity pH 75 involved regula tion Ca2 levels skeletal muscle8384 5 Basic alkaline sphingomyelinases bSMases purified characterized rat intestine bile liver Mg2independent bile saltdepen dent proteaseresistant optimum activity pH 9 958587 32 Gene expression regulation 321 Transcriptional regulation nSMase2 encoded SMPD3 gene studied enzyme sphingomyelinase family Chemotherapeutics 4 16 SINDHU ET AL F I G U R E 2 Schematic representation nSMase2 localization regulation nSMase2 translocate Golgi apparatus plasma membrane process influenced factors The enzymatic activity nSMase2 modulated oxidative stress inflammatory cytokines glutathione chemotherapeutic agents daunorubicin pharmacological inhibitor GW4869 GSH glutathione PKCδ protein kinase C isoformδ PS phosphatidylserine ROS reactive oxygen specie SM sphingomyelin TNFα tumor necrosis factorα Created BioRendercom daunorubicin camptothecin alltrans retinoic acid shown induce transcription SMPD3 gene cancer cells recruiting transcription factors Sp1 Sp3 bind seg ment nucleotides 147 bp upstream exon 1 SMPD3 gene95 In addition obob mouse model T2D asso ciated obesity hyperinsulinemia elevated TNFα lead PKCδ translocation appears independent TNFα effects nSMase2 activation99100 Confluencerelated G0G1 cell cycle arrest MCF7 cells associated translocation nSMase2 protein plasma membrane cytoplasm93 Interestingly HAE cells H2O2 promoted translocation nSMase2 plasma membrane high levels adipose tissue nSMase2 mRNA plasma cer amide96 Similarly subcutaneous adipose tissue samples indi viduals obesity diabetes mRNA levels nSMase generate ceramide cause apoptosis treatment reduced GSH led nSMase2 translocation nucleus enzyme produce ceramide98 Thus nSMAse2 activity localization appear elevated compared nondiabetic obese lean sub jects97 Transcription SMPD3 gene shown elevated fold growtharrested confluent breast cancer MCF7 cells compared controlled cellular redox state nonconfluent cells resultant increase total nSMase activity 323 Modulation nSMase2 activity ceramide levels The increase nSMase2 mRNA levels MCF7 cells correlated G0G1 cell cycle arrest93 Thus nSMase2SMPD3 gene activity appears positively controlled conditions obesity T2D inflammation turned proliferating cancer cells Regulation nSMase2 protein levels 322 localization The expression nSMase2 protein activity HAE lung epi thelial cell line shown enhanced oxidative stress induced hydrogen peroxide H2O2 treatment antioxidant reduced glutathione GSH led decline protein expression98 With respect nSMase2 localization protein kinases p38 PKCδ shown regulate nSMase2 translocation plasma membrane response cytokines TNFα The role The importance nSMase2 ceramidedependent signaling pathways22101 highlighted observations enzymatic activity upregulated phosphatidylserine stress fac tors cytokines IL1β TNFα interferonγ IFNγ oxidative stress reactive oxygen species ROS oxidized lipids UV radia tion chemotherapeutics amyloidβ peptides nitric oxide NO2223102107 The proinflammatory cytokine TNFα direct cou pling receptor shown acutely increase cell free hydrolytic production accumulation ceramide direct nSMase activation108109 It suggested nSMase2 produced plasma membrane activated superoxide O2 associated NADPH oxidase1 signaling cascade involving membraneassociated estrogen receptors110 Interestingly amyloid βpeptide shown directly interact nSMase2 activate enzyme111 A study identified specific serine residues phosphorylated nSMase2 reported oxidative stress SINDHU ET AL 5 16 promotes nSMase2 phosphorylation positively controls activity stability112 By contrast antioxidant agents conditions known S299 close catalytic domain112 Phosphorylation major mechanism nSMase2 activated cytokines TNFα elevated conditions inflammation obesity negatively regulate nSMase activity Thus antioxidant function plasma membrane redox CytB5 reductaseCoQNQO1α insulin resistance In plasma membrane nSMase2 interacts TNFα receptor TNFR1 facilitates PKCδ p38MAPK Tocopherol contains antioxidant ubiquinol mediated nSMase2 phosphorylation regulation Binding shown negatively regulate activity plasma membrane bound nSMase222 nSMase2 activity shown reduced calcineurinmediated dephosphorylation113 GSH antioxi phosphataselike calcineurin leads nSMase2 dephosphorylation decreases activation115 Figure 2 illustrates factors influencing nSMase2 cellular localization activity dant properties shown decrease nSMase activity acting TNFα activation pathways114 Finally inhibitor GW4869 IC50 1 μM enzyme identified high throughput screening It cell membrane permeable non competitive inhibitor widely study nSMase2 functions cell animal models23103 Altogether evidence indicates enzyme regulated 34 metabolic disorders nSMase2 sphingolipids ceramides nSMase2 cellular localization activity protein degradation In different cell types animal models decreased sphingomyelin controlled cytokines ROS cellular redox state levels association elevated ceramides implicated phosphorylation state biological processes control cell differentiation cell cycle arrest programmed cell death106 This topic covered excellent reviews1115118 discussed 33 Structure function properties Because nSMase2 studied neutral SMase implicated inflammation production cytokines Considering significance cellular localization nSMase2 reaction product ceramide cellular signaling important additional processes involved cardiometabolic disorders nSMase2 interesting therapeutic target96119 Below cover understand topology distribution function dif recent understanding role nSMase2 diseases related ferent domains protein plasma membrane nSMase2 nutrient excess metabolic syndrome predicted contain transmembrane segments Nterminal domains NTD Cterminal catalytic domain CAT In addition transmembrane segments catalytic region 35 Insulin signaling insulin resistance collagenous domain function unclear There palmitoylation sites necessary anchoring nSMase2 membrane115 Recent crystallographic studies structure Dysregulated interactions metabolic inflammatory path ways contribute pathogenesis insulin resistance associ human nSMase2 showed interaction ated metabolic complications obesity Metabolic inflammation hydrophobic membrane bound NTD soluble cytosolic CAT domains2694 The juxtamembrane JX NTD region act considered main driver insulin resistance associated metabolic complications120 Obesity induces state chronic low allosteric activator stimulating sphingomyelin hydrolysis grade inflammation hallmark infiltration immune association phospholipids cardiolipin phosphatidylserine1422 elaborated phos It phatidylserine binding NTD juxtamembrane linker region cells fat tissue liver production proinflammatory cytokines chemokines Among proinflammatory cytokines TNFα IL1β produced adipocytes immune cells nSMase2 acts conformational switch leading interdomain intramolecular interactions critical nSMase2 activation116 increase nSMase2 activity production ceramide mediator insulin resistance Figure 3115121122 It revealed asparagine residue ASN130 coordinates binding Mg2 ion active site contributes cat In vitro studies L6 rat skeletal muscle cells showed TNFα ceramide caused attenuation insulin action activation alytic activity nSMase2 stabilizing phosphodiester bond protein phosphatase1 subsequent dephosphorylation inacti sphingomyelin substrate binding site cleavage phosphocholine ceramide26117 In addition region separating NTD CAT domain nSMase2 harbors serine residues phosphorylated115 calcineurinbinding site113 relevant nSMase2 activation stability discussed Oxidative stress shown enhance nSMase2 activity human airway epithelial cells activation associated phosphorylation serine vation AKT SRp40 required insulinstimulated glucose uptake glycogen synthase kinase GSK3β123 It shown ceramide directly activates PKCζ phosphorylates inhibits translo cation AKTPKB124 In addition ceramide stimulates activity cytosolic protein phosphatase2A PP2A dephosphorylates inactivates AKTPKB125126 Thus elevated ceramide levels conditions metabolic syndrome fatty liver disease obe sity appear contribute insulin resistance127128 In addition cer residues S173 S208 near calcineurin binding site S289 S292 amide analogs shown inhibit insulinstimulated glucose 6 16 SINDHU ET AL F I G U R E 3 Pathways insulin signaling inhibition nSMase2 activation ceramides Ceramides produced sphingomyelin nSMase2 activate PKCζ PP2A PKRJNK impair insulin signaling blocking translocation glucose transporter GLUT4 plasma membrane Accumulation ceramides increases proinflammatory cytokine levels lead insulin resistance In addition secreted TNFα IL1β turn activate nSMase2 accelerating ceramide production INSR insulin receptor IRS12 insulin receptor substrates 1 2 PalCoA palmitoyl CoA SM sphingomyelin SMS sphingomyelin synthase TNFR TNFα receptor Created BioRendercom uptake GLUT4 translocation glycogen synthesis isolated brown adipocytes L6 skeletal muscle cells129130 Besides shown ceramide produced nSMase2 accumulates ER contributes ER stress turn causes activation DES1 conducts final step novo synthesis cer amide dihydroceramide shown decrease ceramide dihydroceramide ratios tissues serum prevent diet induced insulin resistance hepatic steatosis mice139 To cJun Nterminal kinase JNK resulting inhibition insulin receptor signaling131 The importance nSMases insulin resistance contrary recent study involving 7 lean healthy volunteers 21 individuals afflicted obesity NAFLD reported decreased demonstrated studies showing inhibition nSMase ceramidedihydroceramide ratio liver plasma leads insu GW4869 protective insulin resistance metabolic dys function cellular stress inflammation induced saturated fatty acid C2C12 skeletal muscle myotubes132 Also nSMase2 inhibition GW4869 abrogated TNFαmediated inflammatory response IL1β MCP1 expression monocytic cells macrophages133 In vivo studies highfat diet fed rodents obob mice Zucker diabetic fatty ZDF rats revealed inhibition ceramide lin resistance fatty liver disease questioning relevance mouse studies human pathology140 Nevertheless total hepatic dihydroceramides lactosylceramide elevated NASH patients comparison patients normal nonalcoholic fatty liver progression NASH141 These studies139143 suggest mechanistic studies required clearly define role ceramide metabolism human disease synthesis administration myriocin inhibitor serine text players ceramide vs dihydroceramide involved insulin palmitoyltransferase led improved insulin sensitivity showing importance ceramides mediators insulin resistance134 Fur thermore antidiabetic drug pioglitazone known pro tect insulin resistance135 activation peroxisome proliferatoractivated receptor gamma PPARγ target genes136137 suppress skeletal muscle TNFα levels associated decrease muscle nSMase2 activity Zucker fatty rats138 pioglitazonemediated suppression suggesting nSMase2 multiple mechanisms improve insulin sensitivity skeletal muscle138 Thus ample vitro vivo evidence indicating enhanced inflammationinduced nSMase activity leads elevated production ceramide pro motes insulin resistance inhibiting ceramide production reducing nSMase activity improves insulin sensitivity Figure 3 Either body liverspecific ablation dihydroceramide desaturase1 resistance NAFLDNASH adipose inflammation 36 Pancreatic ßcell dysfunction death Glucolipotoxicitymediated βcell dysfunction conditions obesity T2D thought increased esterifi cation fatty acylCoA accumulation diacylglycerols ceramides144145 In βcell ceramide synthesis thought predominantly novo pathway starting serine palmitoylCoA146 nSMase2 shown tribute ceramide synthesis conditions ER stress147 nSMase2mediated production ceramide increases ßcells exposed TNFα IL1β contributes damage dys function147 Ceramides accumulate mitochondria alter SINDHU ET AL 7 16 mitochondrial membrane integrity proposed induce apo ptosis necrosis βcells148150 In terms toxicity mechanisms nSMase2 shown synergize BH3only proapoptotic proteins promoting translocation proapoptotic protein Bax mitochondrial membrane triggering opening mitochondrial permeability transition pore release cytochrome c cytosol151 On hand ceramide reported lower inflammation cardiometabolic diseases Lipotoxicity lipid overload contributes cellular organ dysfunction cell death Ceramide accumulation proposed mediate cardiomyocyte apo ptosis induced ischemiareperfusion TNFα palmitate sev eral rodent models obesity diabetes including ZDF rats dbdb obob mice96156 It shown car diomyocyte apoptosis individuals obesity diabetes mRNA expression antiapoptotic protein Bcl2 INS1 βcells activate caspases 37152 It shown human compared lean individuals accompanied elevated expression neutral sphingomyelinase serine palmitoyltransferase empha fatty acidassociated toxic effects mediated islets ceramides Bcl2 downregulation activation caspases153 In presence cytokines IL1β IFNγ human islets undergo ER stress subsequent βcell apoptosis caused ceramide produced action Ca2indepen dent phospholipaseA2β nSMase2148 Thus appears ele vated level ceramide caused enhanced activity nSMase2 induced cytokines glucolipotoxicity trigger mitochon driacytochrome ccaspases37 mediated apoptosis βcells mechanism underlie ßcell failure types 1 2 diabetes forms diabetes characterized islet inflammation elevated levels cytokines It suggested nSMase2 regulates ßcell excit ability insulin granule exocytosis enzyme localizes plasma membrane sphingomyelin147152 Consistent view mice genetic regulates levels sizing potential role altered ceramide metabolism cardiac fail ure patients obesity T2D Figure 455 What mechanism underlies alterations sphingolipid metabolism The saturated fatty acids accumulate TLR4 adipocytes activate tolllike receptor contributes inflammation121149 Adipose tissue inflammation caused increased macrophage recruitment activation leads elevated production proinflammatory cytokines TNFα IL1β We recently showed disruption nSMase2 activity aSMase TNFαdriven inflammatory responses monocytes macrophages prevents including expression inflammatory M1 macrophage marker CD11c secretion prototypic inflammatory mediators IL1β MCP1133 The evidence indicated inhibition TNFαdriven inflamma tory responses involves NFκBMAPK signaling pathway In agreement data peripheral blood mononuclear cells deletion sphingomyelin synthase1 converts ceramide PBMC individuals obesity shown display sphingomyelin display increased ceramide accumulation mitochon drial degeneration increased ROS production βcells accompanied defective glucosestimulated insulin secretion154 Sur prisingly shown recent study mice ceramide levels increased cigarette smoking cause oxidative ER stress βcells leading reduced insulin production processing secretion decreased viability proliferation βcells155 Also shown inhibiting formation cer amide protects βcells destruction T2D rodent models149155 Thus mounting evidence supports role nSMase2 ceramides development βcell dysfunction failure increased levels nSMase2 known associate TNFα expression cells These findings collectively support view nSMase2 acts master switch TNFαmediated inflammatory responses monocytes macro phages obesity setting133 As detailed section ceramides nSMase2 appear contribute development βcell failure T2D Many stud ies shown blocking lowering ceramide accumulation tissues improves diabetic condition16134139148149157 High levels dietary fiber known lower risk coronary heart disease associated mortality recent study revealed T2D However order better understand precise role nSMase2 βcell function health disease studies employing animal models βcell specific deletion dietary fiber inulin reduces expression liver nSMase2 plasma ceramide levels major risk factor cardiometabolic diseases158 Overall significant evidence suggests nSMase2SMPD3 gene needed Whole body nSMase2 knockout inhibition ceramide generation nSMase2 path mice display significant growth retardation ways help prevent adipose inflammation monocytemacro form dwarfism hypothalamusinduced combined pituitary hormone phage activation retard development T2D deficiency abnormalities skeletal development Glucose insulin homeostasis studied mice29 metabolic syndromerelated disorders Obesity T2D associated inflammatory 37 conditions 38 NAFLDNASH NAFLD represents group pathologies include hepatic steatosis NASH fibrosis cirrhosis159 underlying patho Excess energy intake leads accumulation fat adipose tis genic mechanisms multifactorial complex Even sues ectopically tissues liver skeletal muscle NAFLD highly prevalent general population affected myocardium leading obesity associated patients suffer mainly nonlife threatening simple steatosis 8 16 SINDHU ET AL Proposed role nSMase2 ceramides pathogenesis different metabolic diseases The chronic lowgrade inflammation F I G U R E 4 individuals obesity drives production proinflammatory cytokines TNFα IL1β lead upregulation nSMase2 expression activity This turn increases production ceramides leading mitochondrial dysfunction production reactive oxygen species ROS insulin resistance Accumulation ceramides different organs responsible onset different metabolic diseases Created BioRendercom 510 patients NAFLD actually develop NASH patients progressing cirrhosis160 The NAFLD140 Similarly recent clinical study involving 288 patients rev ealed association NAFLD spectrum plasma twohit hypothesis NAFLD pathogenesis states life levels typical sphingolipids long chain sphingoid base styleinduced lipid accumulation liver acts hit sensitizes liver second hits ERoxidative stress161162 proinflammatory cytokines163164 lipotoxicity165 leading containing sphingosine sphinganine elevated plasma deoxysphingolipid levels noticed patients steatosis179 These deoxysphingolipids generated serine palmitoyl steatohepatitis fibrosis However simplistic view rep laced multiple hit hypothesis proposes multiple hits implicated NAFLD pathogenesis dietary factors transferase SPT condensation palmitoylCoA Lalanine Lglycine amino acids present excess instead serine180 In addition missense mutations C133W gut microbiota insulin resistance adipokines genetic epigenetic C133Y V144D G387A SPT1LC subunit SPT enzyme factors acting combination genetically predisposed subjects eventually lead NAFLD160166 Sphingolipids impli shift substrate specificity mutated SPT serine alanine glycine leading accumulation cated pathogenesis progression steatosis NAFLD unmetabolizable deoxysphingolipids resulting hereditary dis evidence studies different based murine163167174 rat models175178 NAFLD suggesting reduction certain sphingolipids like ceramide likely beneficial NAFLDNASH159167178 However importance cer amide human NAFLDNASH questioned recently Thus hereditary type ease 1 HSNA1181 Because lack C1hydroxyl group deoxy neuropathy autonomic sensory sphingolipids metabolized sphingolipid catabolism path ways partly metabolized enzymes cytochrome P450 subfamily180182 The plasma levels deoxysphingolipids prevention hepatic steatosis observed model body liverspecific DES1 deletion mice139 decreasing tissue plasma ceramidedihydroceramide ratios elevated patients metabolic syndrome T2D183184 nonalcoholic steatohepatitis185 diabetic sensory poly neuropathy186 Thus precise pathogenic role elevated nontranslatable humans reverse noticed study com sphingolipids onset NAFLD unclear lipids paring lean healthy individuals patients obesity appear associated steatosis mechanistic clinical SINDHU ET AL 9 16 studies required clearly define role ceramide metabolism atherogenic plaques heart failure195200 Figure 4 The tempo NAFLDNASH pathogenesis ral profiling regulatory enzymes involved myocardial ceramide There significant evidence role acid SMase metabolism revealed elevated synthesis accumulation highly expressed liver NASH role nSMase2 relatively expressed liver established187 ceramides associated cardiovascular disease mortality patients coronary artery disease201202 In vascular cells Indeed studies assessing liver gene expression changes fatty liver disease humans reported link nSMase2188189 A role including nSMase2 activated number stress stimuli proinflammatory cytokines TNFα IL1β IL6 IFNγ unsatu nSMase2 hepatic steatosis emerges studies mice far strong human disease relevance190 rated fatty acids oxidized LDL anionic phospholipids oxidative stress antioxidants GSH inhibit enzyme119203 Inasmuch elevated ceramides positively regulate expression release proinflammatory cytokines known The induction activation nSMase2 involve activation TNFα receptor related cofactorsadapter proteins factor play important role steatohepatitis dysregulation associated nSMase FAN cardiomyocyteassociated Polycomb nSMase2 shown contribute inflammation stud ies needed ascertain role nSMase2 human NAFLD NASH pathogenesis 39 Atherosclerosis protein embryonic ectodermal development EED prote ase cascade consisting furin matrix metalloprotease2204205 It shown model postmyocardial infarction failing rat hearts activation nSMase2 leads apoptosis left ventricular cardiomyocytes caspase3 activation206 Indeed nSMase2 inhibi tion reduction circulating ceramide levels Nacetylcysteine lipoic acid shown beneficial Atherosclerosis marked accumulation plaque atheroma vascular endothelium Atherosclerotic plaque formation involves aggregation atherogenic lipoproteins play important role initiation progression atherosclerosis191 reducing rat endothelial dysfunction improving postmyocardial infarction failing hearts rats206207 There evidence animal model studies implicating nSMase2 cardiac failure mech anistic studies animals needed clinical studies Lipoprotein aggregation occur process ascertain nSMase2 plays role human heart failure ceramide pho sphingomyelin hydrolysis SMases sphocholine192193 Lowdensity lipoproteins LDL oxidized LDL groups lipids sphingolipids ceramides produced target therapy aSMases nSMases glycosphingolipids 311 Exosomes nSMase2 glucosylceramide lactosylceramide proposed tribute atherosclerotic process thrombotic diseases194195 Ceramide lactosylceramide involved apopto sis wildtype human osteosarcoma cell line MG63 action nSMases196 lactosylceramide cause human aortic smooth muscle cell proliferation led plaque formation194197 Many types cells release lipid bilayer membrane vesicles extracellularly208 vesicles contain cellular compo nents including cytosolic proteins microRNAs mRNAs membrane topology transmembrane proteins cells209 Extracellular vesicles originating intraluminal vesicles Ceramides induce systemic proinflammatory responses called exosomes released fusion endosomes accumulation glycosphingolipids lead induction adhe sion molecules vascular endothelial cells activating neu trophils triggering plaque inflammation198 Likewise Lallemand et al reported deficiency nSMase2 mice inhibition GW4869 attenuated inflammation atherosclerosis Apoe mice199 Also recent study LDL receptordeficient mouse model atherosclerosis revealed dietary inulin reduced liver expression nSMase2 plasma ceramides prevented risk atherosclerosis mice158 Thus interplay nSMase2 inflammation lipoproteins appears involved pathogenesis atherosclerosis 310 Heart failure nSMases appear involved cardiovascular pathophysiological processes cardiomyocyte proliferation death vascular plasma membrane subsequent accumulation exosomes endosomes210 Several studies implicated exosomes cell cell communication transport large molecules cell cell209210 Involvement exosomes development pathological conditions diabetes complications Alzheimers disease cancer metastasis immune suppression obesity related complications including inflammation recog nized211 Lipids play important role biogenesis exosomes particularly nSMase2 product ceramide shown contribute exosome production intraluminal vesicle bud ding212213 Thus exosomes shown enriched cer amide sphingomyelin compared parent cells212214 An important role nSMase2 ceramide exosomemediated miRNA secretion suggested studies HEK293 cells metastatic MDAMB231 breast cancer cells suppres sion nSMase2 activity inhibitor GW4869 RNAi knock nSMase2 overexpression215216 Ceramide synthesis smooth muscle cell contraction lipotoxic cardiomyopathy formation nSMase2 shown facilitate exosomesmediated transfer 10 16 SINDHU ET AL high molecular weight aggregates αsynuclein tau prion pro better understanding pathophysiological roles enzyme teins contribute spread neurodegenerative diseases217219 Importance exosomes cardiometabolic diseases emphasized recent study showing visceral adipose different organs assessing therapeutic value nSMase2 inhibition Such animal models needed answer uncertainties regard vivo role nSMase2 diseases exosomes pregnant obese mice contribute fetal cardiac dysfunc tion220 Interestingly exosomes secreted adipocytes response like NAFLD atherosclerosis heart failure Such animal models needed verify involvement nSMase2 ceramide ER stress induce steatosis inflammation fibrosis liver lead NASH alteration hepatic lipid dynamics221 vivo secretion exosomes mediate intercellular com munications lead pathological conditions In addition Also recently shown intestinal exosomes released studies human tissuescells normal highfat diet fed mice T2D patients induce insulin resis tance normal mice222 Pancreatic βcells exposed pathological conditions needed better define relevance nSMase2 human physiology pathology Also currently increased fatty acid levels vitro vivo mice available pharmacological agents appear entirely specific shown release exosomes packed miR29 involved antagonizing insulin signaling liver223 Additionally INS1E βcells nSMase2 studies needed develop specific nSMase2 inhibitors pharmacological evaluation nSMase2 overexpressing human islet amyloid polypeptide hIAPP therapeutic target shown secrete exosomes packed hIAPP detoxification process released hIAPP loaded exosomes lead neuro degenerative diseases224 On hand miR690 ACKNOWLEDG MENTS This study supported funds Montreal Medical exosomes M2polarized bone marrowderived macro InternationalDasman Diabetes Institute MP SRMM RA phages exosomes miR690 shown improve Canadian Institutes Health Research MP insulin sensitivity glucose tolerance mice vitro vivo225 Inasmuch nSMase2 ceramide likely play SRMM important role exosome release likely nSMase2 CONFLIC T OF INT ER E ST ceramidemediated mechanisms involved pathologi No conflict declared cal conditions cell cell communications facilitated exosomes However convincing studies needed animal OR CID models genetic alteration nSMase2 expression Hossein Arefanian httpsorcidorg0000000164140916 earlier studies nSMase2 inhibitor RNAi S R Murthy Madiraju httpsorcidorg0000000226132074 knockdown 4 C O N C L U S I O N S A N D P ER SP EC TI V E Sphingolipids important membrane structural components impli cated cellular signaling pathways pathogenesis inflammation cardiometabolic diseases cancer Dysregulation nSMase2 encoded SMPD3 gene appears underlie inflammationrelated pathologies elevated syn thesis ceramides Ample evidence supports view nSMase2 activated increased oxidized state ROS proinflammatory cytokines known causative factors inflammation βcell dysfunction insulin resistance T2D NAFLDNASH ath erosclerosis Indeed feedforward interaction likely exists enhanced ceramide formation nSMase2 production proinflammatory cytokines TNFα IL1β Through cyclical interaction proinflammatory cytokines enhance activity nSMase2 ceramide produced increases synthesis release cytokines Considering interaction RE FE RE NCE S 1 Pralhada Rao R Vaidyanathan N Rengasamy M Mammen Oommen A Somaiya N Jagannath MR Sphingolipid metabolic path way overview major roles played human diseases J Lipids 20132013178910 2 Russo SB Ross JS Cowart LA Sphingolipids obesity type 2 diabe tes metabolic disease Handb Exp Pharmacol 2013216 373401 3 Ng ML Wadham C Sukocheva OA The role sphingolipid signal Int J Mol Med ling diabetesassociated pathologies Review 2017392243252 4 Sui J He M Wang Y Zhao X He Y Shi B Sphingolipid metabolism type 2 diabetes associated cardiovascular complications Exp Ther Med 201918536033614 5 Ogretmen B Sphingolipid metabolism cancer signalling ther apy Nat Rev Cancer 20181813350 6 Ghidoni R Caretti A Signorelli P Role sphingolipids patho Inflamm 20152015 lung inflammation Mediators biology 487508 7 Chakinala RC Khatri A Gupta K Koike K Epelbaum O Sphingolipids COPD Eur Respir Rev 201928154190047 8 Platt FM Sphingolipid lysosomal storage disorders Nature 2014 nSMase2 inflammatory cytokines trigger elevated 51075036875 cellular ROS levels inflammation contribute patho genesis cardiometabolic diseases specific blockade nSMase2 therapeutic effects However considering constitu tive body deletion nSMase2 causes growth retardation mice need tissuespecific conditional knockout mice 9 Bielawska A Linardic CM Hannun YA Ceramidemediated biology Determination structural stereospecific requirements use Nacylphenylaminoalcohol analogs J Biol Chem 1992 267261849318497 10 Clarke CJ Mediwala K Jenkins RW Sutton CA Tholanikunnel BG Hannun YA Neutral sphingomyelinase2 mediates growth arrest SINDHU ET AL 11 16 retinoic acid modulation ribosomal S6 kinase J Biol Chem 2011286242156521576 11 Sharma K Shi Y The yins yangs ceramide Cell Res 199991 110 12 Arana L Gangoiti P Ouro A Trueba M GómezMuñoz A Ceramide ceramide 1phosphate health disease Lipids Health Dis 20109115 13 Venable ME Lee JY Smyth MJ Bielawska A Obeid LM Role cer amide cellular senescence J Biol Chem 19952705130701 30708 14 Kuzmenko DI Klimentyeva TK Role ceramide apoptosis development insulin resistance Biochemistry Mosc 2016819 913927 15 Sokolowska E BlachnioZabielska A The role ceramides insulin resistance Front Endocrinol 201910577 16 SchmitzPeiffer C Targeting ceramide synthesis reverse insulin resistance Diabetes 2010591023512353 17 AndrieuAbadie N Gouazé V Salvayre R Levade T Ceramide apoptosis signaling relationship oxidative stress Free Radic Biol Med 2001316717728 18 Bismuth J Lin P Yao Q Chen C Ceramide common pathway atherosclerosis Atherosclerosis 20081962497504 19 Wit NM den Hoedt S MartinezMartinez P Rozemuller AJ Mulder MT Vries HE Astrocytic ceramide possible indicator neuroinflammation J Neuroinflammation 201916148 20 Schneider PB Kennedy EP Sphingomyelinase normal human spleens spleens subjects NiemannPick disease J Lipid Res 196783202209 21 Rao BG Spence MW Sphingomyelinase activity pH 74 human brain comparison activity pH 50 J Lipid Res 1976175 506515 22 Clarke CJ Hannun YA Neutral sphingomyelinases nSMase2 bridging gaps Biochim Biophys Acta 200617581218931901 23 Shamseddine AA Airola MV Hannun YA Roles regulation neutral sphingomyelinase2 cellular pathological processes Adv Biol Regul 2015572441 24 Clarke CJ Snook CF Tani M Matmati N Marchesini N Hannun YA The extended family neutral sphingomyelinases Biochemistry 200645381124711256 25 Karakashian AA Giltiay NV Smith GM NikolovaKarakashian MN Expression neutral sphingomyelinase2 NSMase2 primary rat hepatocytes modulates ILbetainduced JNK activation FASEB J 2004189968970 26 Airola MV Shanbhogue P Shamseddine AA et al Structure human nSMase2 reveals interdomain allosteric activation mecha nism ceramide generation Proc Natl Acad Sci U S A 2017114 28E5549E5558 2 27 Clarke CJ Cloessner EA Roddy PL Hannun YA Neutral sphingomyelinase neutral nSMase2 sphingomyelinase isoform activated tumour necrosis factoralpha MCF7 cells Biochem J 20114352381390 28 Kim MY Linardic C Obeid L Hannun Y Identification sphingomyelin turnover effector mechanism action tumor necrosis factor alpha gammainterferon Specific role cell differentiation J Biol Chem 19912661484489 primary 29 Stoffel W Jenke B Block B Zumbansen M Koebke J Neutral sphingomyelinase 2 smpd3 control postnatal growth development Proc Natl Acad Sci U S A 200510212 45544559 30 Khavandgar Z Poirier C Clarke CJ et al A cellautonomous require ment neutral sphingomyelinase 2 bone mineralization J Cell Biol 20111942277289 31 Strum JC Ghosh S Bell RM Lipid second messengers A role cell growth regulation cell cycle progression Adv Exp Med Biol 1997407421431 32 Devillard R Galvani S Thiers JC et al Stressinduced sphingolipid signaling role type2 neutral sphingomyelinase murine cell apo ptosis proliferation PLoS One 201053e9826 33 Trayssac M Hannun YA Obeid LM Role sphingolipids senes cence implication aging agerelated diseases J Clin Invest 2018128727022712 34 Jarvis WD Kolesnick RN Fornari FA Traylor RS Gewirtz DA Grant S Induction apoptotic DNA damage cell death acti vation sphingomyelin pathway Proc Natl Acad Sci U S 19949117377 35 Gills JJ Zhang C AbuAsab MS et al Ceramide mediates nanovesicle shedding cell death response pho sphatidylinositol ether lipid analogs perifosine Cell Death Dis 20123e340 36 Back MJ Ha HC Fu Z neutral sphingomyelinase 2 starvation induces cellprotective autophagy increase Golgilocalized ceramide Cell Death Dis 20189 6670 al Activation et 37 Thery C Zitvogel L Amigorena S Exosomes composition biogene sis function Nat Rev Immunol 200228569579 38 Kosaka N Iguchi H Hagiwara K Yoshioka Y Takeshita F Ochiya T Neutral sphingomyelinase 2 nSMase2dependent exosomal trans fer angiogenic microRNAs regulate cancer cell metastasis J Biol Chem 2013288151084910859 39 Yang Z Costanzo M Golde DW Kolesnick RN Tumor necrosis fac tor activation sphingomyelin pathway signals nuclear factor kappa B translocation intact HL60 cells J Biol Chem 1993268 272052020523 40 Szabo G Csak T Inflammasomes liver diseases J Hepatol 2012 573642654 41 Dobierzewska A Shi L Karakashian AA NikolovaKarakashian MN Interleukin 1beta regulation FoxO1 protein content localiza tion evidence novel ceramidedependent mechanism J Biol Chem 2012287534474944760 42 Henry B Moller C DimancheBoitrel MT Gulbins E Becker KA Targeting ceramide cancer Cancer Lett 20133322 286294 43 Park B Lee YM Kim JS et al Neutral sphingomyelinase 2 modulates cytotoxic effects protopanaxadiol different human cancer cells BMC Complement Altern Med 201313194 44 Farkas E Luiten PG Cerebral microvascular pathology aging Alzheimers disease Prog Neurobiol 2001646575611 45 Saxena S Caroni P Selective neuronal vulnerability neurodegen erative diseases stressor thresholds degeneration Neuron 20117113548 46 Poirier C Berdyshev EV Dimitropoulou C Bogatcheva NV Biddinger PW Verin AD Neutral sphingomyelinase 2 deficiency associated lung anomalies similar emphysema Mamm Genome 2012231112758763 47 Cogolludo A Moreno L Frazziano G et al Activation neutral sphingomyelinase involved acute hypoxic pulmonary vasocon striction Cardiovasc Res 2009822296302 48 Smith AR Visioli F Frei B Hagen TM Agerelated changes endo thelial nitric oxide synthase phosphorylation nitric oxide depen dent vasodilation evidence novel mechanism involving sphingomyelinase ceramideactivated phosphatase 2A Aging Cell 200655391400 49 Mogami K Kishi H Kobayashi S Sphingomyelinase causes endotheliumdependent vasorelaxation endothelial nitric oxide production cytosolic Ca2 elevation FEBS Lett 20055792393397 50 Ohanian J Forman SP Katzenberg G Ohanian V Endothelin1 stim small artery VCAM1 expression p38MAPK J Vasc Res 2012494 ulates dependent neutral sphingomyelinase 353362 12 16 SINDHU ET AL 51 Altura BM Shah NC Shah GJ et al Magnesium deficiency upregulates sphingomyelinases cardiovascular tissues cells crosstalk protooncogenes Mg2 NFkappaB cer amide potential relationships resistant hypertension atherogenesis cardiac failure Int J Clin Exp Med 2013610 861879 52 Altura BM Shah NC Shah GJ et al Shortterm Mg deficiency upregulates protein kinase C isoforms cardiovascular tissues cells relation NFkB cytokines ceramide salvage sphingolipid pathway PKCzeta hypothesis review Int J Clin Exp Med 201471121 53 Shah NC Shah GJ Li Z Jiang XC Altura BT Altura BM Shortterm magnesium deficiency downregulates telomerase upregulates neu tral sphingomyelinase induces oxidative DNA damage cardio vascular tissues relevance atherogenesis cardiovascular diseases aging Int J Clin Exp Med 201473497514 54 Hernandez OM Discher DJ Bishopric NH Webster KA Rapid acti vation neutral sphingomyelinase hypoxiareoxygenation cardiac myocytes Circ Res 2000862198204 55 Baranowski M BlachnioZabielska A Hirnle T et al Myocardium type 2 diabetic obese patients characterized alterations sphingolipid metabolic enzymes accumulation cer amide J Lipid Res 20105117480 72 Henry B Ziobro R Becker KA Kolesnick R Gulbins E Acid sphingomyelinase Handb Exp Pharmacol 20132157788 73 Barnholz Y Roitman A Gatt S Enzymatic hydrolysis sphingolipids II Hydrolysis sphingomyelin enzyme rat brain J Biol Chem 19662411637313737 74 Tabas I Secretory sphingomyelinase Chem Phys Lipids 1999102 12123130 75 Schissel SL Keesler GA Schuchman EH Williams KJ Tabas I The cellular trafficking zinc dependence secretory lysosomal sphingomyelinase products acid sphingomyelinase gene J Biol Chem 1998273291825018259 76 Schissel SL Jiang X TweedieHardman J et al Secretory sphingomyelinase product acid sphingomyelinase gene hydrolyze atherogenic lipoproteins neutral pH Implications atherosclerotic lesion development J Biol Chem 19982735 27382746 77 Krut O Wiegmann K Kashkar H Yazdanpanah B Kronke M Novel factorresponsive mammalian neutral sphingomyelinase3 Ctailanchored protein J Biol Chem 2006 281191378413793 tumor necrosis 78 Tani M Ito M Igarashi Y Ceramidesphingosinesphingosine 1phosphate metabolism cell surface extracellular space Cell Signal 2007192229237 56 Thudichum JLW A Treatise Chemical Constitution Brain 79 AndrieuAbadie N Levade T Sphingomyelin hydrolysis Vol 22 London Bailliere Tindall Cox 1884146 apoptosis Biochim Biophys Acta 2002158523126134 57 Hannun YA Obeid LM Principles bioactive lipid signalling les sons sphingolipids Nat Rev Mol Cell Biol 200892139150 58 Hannun YA Luberto C Lipid metabolism ceramide transfer protein adds new dimension Curr Biol 2004144R163R165 80 Czarny M Schnitzer JE Neutral sphingomyelinase inhibitor scyphostatin prevents ceramide mimics mechanotransduction vascular endothelium Am J Physiol Heart Circ Physiol 20042873 H1344H1352 59 Gault CR Obeid LM Hannun YA An overview sphingolipid metabolism synthesis breakdown Adv Exp Med Biol 2010 688123 60 Hannun YA Obeid LM Sphingolipids metabolism physi 81 Auge N Andrieu N NegreSalvayre A Thiers JC Levade T Salvayre R The sphingomyelinceramide signaling pathway involved oxidized low density lipoproteininduced cell prolifera tion J Biol Chem 1996271321925119255 ology disease Nat Rev Mol Cell Biol 2018193175191 82 Chatterjee S Neutral sphingomyelinase past present future 61 Menaldino DS Bushnev A Sun A et al Sphingoid bases novo ceramide synthesis enzymes involved pharmacology mecha nisms action Pharmacol Res 2003475373381 62 Kolter T Sandhoff K Principles lysosomal membrane digestion stimulation sphingolipid degradation sphingolipid activator proteins anionic lysosomal lipids Annu Rev Cell Dev Biol 2005 2181103 63 Snook CF Jones JA Hannun YA Sphingolipidbinding proteins Biochim Biophys Acta 200617618927946 64 Zeidan YH Hannun YA Translational aspects sphingolipid metab olism Trends Mol Med 2007138327336 65 Aburasayn H Al Batran R Ussher JR Targeting ceramide metabo lism obesity Am J Physiol Endocrinol Metab 20163112 E423E435 66 GarciaGonzalez V DiazVillanueva JF GalindoHernandez O MartinezNavarro I HurtadoUreta G PerezArias AA Ceramide metabolism balance multifaceted factor critical steps breast cancer development Int J Mol Sci 20181992527 67 Weiss B Stoffel W Human murine serinepalmitoylCoA transferasecloning expression characterization key enzyme sphingolipid synthesis Eur J Biochem 19972491 239247 68 Hannun YA Obeid LM Ceramide intracellular signal apopto sis Trends Biochem Sci 19952027377 69 Kitatani K IdkowiakBaldys J Hannun YA The sphingolipid salvage pathway ceramide metabolism signaling Cell Signal 2008 20610101018 70 Goni FM Alonso A Sphingomyelinases enzymology membrane activity FEBS Lett 200253113846 71 Marchesini N Hannun YA Acid neutral sphingomyelinases roles mechanisms regulation Biochem Cell Biol 20048212744 Chem Phys Lipids 1999102127996 83 Ghosh N Sabbadini R Chatterjee S Identification partial purifica tion localization neutral sphingomyelinase rabbit skeletal muscle neutral sphingomyelinase skeletal muscle Mol Cell Biochem 199818912161168 84 Okazaki T Bielawska A Domae N Bell RM Hannun YA Character istics partial purification novel cytosolic magnesium independent neutral sphingomyelinase activated early signal transduction 1 alpha25dihydroxyvitamin D3induced HL60 cell differentiation J Biol Chem 1994269640704077 85 Nilsson A Duan RD Alkaline sphingomyelinases ceramidases gastrointestinal tract Chem Phys Lipids 19991021297105 86 Cheng Y Nilsson A Tomquist E Duan RD Purification characteriza tion expression rat intestinal alkaline sphingomyelinase J Lipid Res 2002432316324 87 Duan RD Alkaline sphingomyelinase old enzyme novel implications Biochim Biophys Acta 200617613281291 characterization 88 Liu B Hassler DF Smith GK Weaver K Hannun YA Purification pH optimum magnesiumdependent phosphatidylserinestimulated J Biol Chem 199827351 sphingomyelinase rat brain 3447234479 membrane neutral bound 89 Bernardo K Krut O Wiegmann K et al Purification characteri zation magnesiumdependent neutral sphingomyelinase bovine brain J Biol Chem 20002751176417647 90 Tomiuk S Zumbansen M Stoffel W Characterization subcellular localization murine human magnesiumdependent neutral sphingomyelinase J Biol Chem 2000275857105717 91 Hofmann K Tomiuk S Wolff G Stoffel W Cloning characteriza mammalian brainspecific Mg2dependent neutral tion sphingomyelinase Proc Natl Acad Sci U S A 2000971158955900 SINDHU ET AL 13 16 92 Aubin I Adams CP Opsahl S et al A deletion gene encoding sphingomyelin phosphodiesterase 3 Smpd3 results osteogenesis dentinogenesis imperfecta mouse Nat Genet 2005378 803805 93 Marchesini N Osta W Bielawski J Luberto C Obeid LM Hannun YA Role mammalian neutral sphingomyelinase 2 confluenceinduced growth arrest MCF7 cells J Biol Chem 2004 279242510125111 94 Tani M Hannun YA Analysis membrane topology neutral sphingomyelinase 2 FEBS Lett 2007581713231328 95 sphingomyelinase 2 alltrans Ito H Tanaka K Hagiwara K et al Transcriptional regulation retinoic acidtreated neutral human breast cancer cell line MCF7 J Biochem 20121516 599610 96 Samad F Hester KD Yang G Hannun YA Bielawski J Altered adi pose plasma sphingolipid metabolism obesity potential mechanism cardiovascular metabolic risk Diabetes 200655 925792587 97 BlachnioZabielska AU Koutsari C Tchkonia T Jensen MD Sphingolipid content human adipose tissue relationship adiponectin insulin resistance Obesity Silver Spring 201220 1223412347 98 Levy M Castillo SS Goldkorn T nSMase2 activation trafficking modulated oxidative stress induce apoptosis Biochem Biophys Res Commun 20063443900905 99 Clarke CJ Truong YA Role TG Hannun neutral sphingomyelinase2 tumor necrosis factor alphastimulated expression vascular cell adhesion molecule1 VCAM inter cellular adhesion molecule1 ICAM lung epithelial cells p38 MAPK upstream regulator nSMase2 J Biol Chem 2007282 213841396 100 Clarke CJ Guthrie JM Hannun YA Regulation neutral sphingomyelinase2 nSMase2 tumor necrosis factoralpha involves protein kinase Cdelta lung epithelial cells Mol Pharmacol 200874410221032 101 Horres CR Hannun YA The roles neutral sphingomyelinases neurological pathologies Neurochem Res 201237611371149 102 Rutkute K Asmis RH NikolovaKarakashian MN Regulation neu tral sphingomyelinase2 GSH new insight role oxida tive stress agingassociated inflammation J Lipid Res 200748 1124432452 103 Luberto C Hassler DF Signorelli P et al Inhibition tumor necrosis factorinduced cell death MCF7 novel inhibitor neutral sphingomyelinase J Biol Chem 2002277434112841139 104 Palma C Meacci E Perrotta C Bruni P Clementi E Endothelial nitric oxide synthase activation tumor necrosis factor alpha neutral sphingomyelinase 2 sphingosine kinase 1 sphingosine 1 phosphate receptors novel pathway relevant pathophysiology endothelium Arterioscler Thromb Vasc Biol 200626199105 105 Zeng C Lee JT Chen H Chen S Hsu CY Xu J Amyloidbeta peptide enhances factoralphainduced iNOS neutral sphingomyelinaseceramide pathway oligoden drocytes J Neurochem 2005943703712 tumor necrosis 106 Marchesini N Luberto C Hannun YA Biochemical properties mammalian neutral sphingomyelinase 2 role sphingolipid metabolism J Biol Chem 2003278161377513783 Ito H Murakami M Furuhata A et al Transcriptional regulation neutral sphingomyelinase 2 gene expression human breast cancer cell induced anticancer drug daunorubicin Biochim Biophys Acta 200917891112681690 line MCF7 107 108 Dressler KA Mathias S Kolesnick RN Tumor necrosis factoralpha activates sphingomyelin signal transduction pathway cell free Science 1992255505217151718 110 109 Wiegmann K Schutze S Machleidt T Witte D Kronke M Func tional dichotomy neutral acidic sphingomyelinases tumor necrosis factor signaling Cell 199478610051015 Ishii T Warabi E Mechanism rapid nuclear factorE2related fac tor 2 Nrf2 activation membraneassociated estrogen receptors roles NADPH oxidase 1 neutral sphingomyelinase 2 epidermal growth factor receptor EGFR Antioxidants Basel 2019 8369 111 Grimm MO Grimm HS Patzold AJ et al Regulation cholesterol sphingomyelin metabolism amyloidbeta presenilin Nat Cell Biol 200571111181123 112 Filosto S Ashfaq M Chung S Fry W Goldkorn T Neutral sphingomyelinase 2 activity protein stability modulated phosphorylation conserved serines J Biol Chem 20122871 514522 113 Filosto S T Neutral Fry W Knowlton AA Goldkorn sphingomyelinase 2 nSMase2 phosphoprotein regulated cal cineurin PP2B J Biol Chem 2010285141021310222 114 Liu B AndrieuAbadie N Levade T Zhang P Obeid LM Hannun YA Glutathione regulation neutral sphingomyelinase tumor necro sis factoralphainduced cell death J Biol Chem 199827318 1131311320 115 Airola MV Hannun YA Sphingolipid metabolism neutral sphingomyelinases Handb Exp Pharmacol 20132155776 116 Shanbhogue P Hoffmann RM Airola MV et al The juxtamembrane linker neutral sphingomyelinase2 functions intramolecular allosteric switch activates enzyme J Biol Chem 2019294 1874887502 117 Ago H Oda M Takahashi M basis sphingomyelin phosphodiesterase activity neutral sphingomyelinase Bacillus cereus J Biol Chem 200628123 1615716167 Structural al et 118 Bartke N Hannun YA Bioactive sphingolipids metabolism func tion J Lipid Res 200950 SupplSupplS91S96 119 Pavoine C Pecker F Sphingomyelinases regulation roles cardiovascular pathophysiology Cardiovasc Res 2009822 175183 120 Wu H Ballantyne CM Metabolic inflammation insulin resis tance obesity Circ Res 20201261115491564 121 Li Y Talbot CL Chaurasia B Ceramides adipose tissue Front Endocr Lausanne 202011407 122 NikolovaKarakashian M Karakashian A Rutkute K Role neutral sphingomyelinases aging inflammation Subcell Biochem 200849469486 123 Ghosh N Patel N Jiang K et al Ceramideactivated protein phos phatase involvement insulin resistance Akt serinearginine rich protein 40 ribonucleic acid splicing L6 skeletal muscle cells Endocrinology 2007148313591366 124 Powell DJ Hajduch E Kular G Hundal HS Ceramide disables 3phosphoinositide binding pleckstrin homology domain protein kinase B PKBAkt PKCzetadependent mechanism Mol Cell Biol 2003232177947808 125 Chavez JA Knotts TA Wang LP et al A role ceramide diacylglycerol antagonism insulin signal transduction saturated fatty acids J Biol Chem 2003278121029710303 126 Resjo S Goransson O Harndahl L Zolnierowicz S Manganiello V Degerman E Protein phosphatase 2A main phosphatase involved regulation protein kinase B rat adipocytes Cell Signal 2002143231238 127 Turpin SM Nicholls HT Willmes DM et al Obesityinduced CerS6dependent C160 ceramide production promotes weight gain glucose intolerance Cell Metab 2014204678686 128 KonstantynowiczNowicka Baranowski M Chabowski A New evidence role ceramide develop ment hepatic insulin resistance PLoS One 2015101e0116858 K Harasim E 14 16 SINDHU ET AL 129 FernandezVeledo S Hernandez R Teruel T Mas JA Ros M Lorenzo M Ceramide mediates TNFalphainduced insulin resis tance GLUT4 gene expression brown adipocytes Arch Physiol Biochem 200611211322 130 Hajduch E Balendran A Batty IH et al Ceramide impairs insulindependent membrane recruitment protein kinase B lead ing loss downstream signalling L6 skeletal muscle cells Diabetologia 2001442173183 131 Ozcan U Cao Q Yilmaz E et al Endoplasmic reticulum stress links insulin action type 2 diabetes Science 2004306 obesity 5695457461 132 Verma MK Yateesh AN Neelima K et al Inhibition neutral sphingomyelinases skeletal muscle attenuates fattyacid induced defects metabolism stress Springerplus 20143255 133 AlRashed F Ahmad Z Thomas R et al Neutral sphingomyelinase 2 regulates inflammatory responses monocytesmacrophages induced TNFα Sci Rep 202010116802 134 Holland WL Brozinick JT Wang LP et al Inhibition ceramide synthesis ameliorates glucocorticoid saturatedfat obesity induced insulin resistance Cell Metab 200753167179 135 Miyazaki Y Matsuda M DeFronzo RA Doseresponse effect pioglitazone insulin sensitivity insulin secretion type 2 dia betes Diabetes Care 2002253517523 136 Sakamoto J Kimura H Moriyama S et al Activation human subtypes oxisome proliferatoractivated receptor pioglitazone Biochem Biophys Res Commun 20002783704711 PPAR proinflammatory cytokines suggests role iPLA2beta T1D development Endocrinology 2014155933523364 149 Ying L Tippetts TS Chaurasia B Ceramide dependent lipotoxicity metabolic diseases Nutr Heal Ag 201951112 150 Véret J Bellini L Giussani P Ng C Magnan C Stunff HL Roles sphingolipid metabolism pancreatic β cell dysfunction induced lipotoxicity J Clin Med 201432646662 151 Chipuk JE McStay GP Bharti A et al Sphingolipid metabolism cooperates BAK BAX promote mitochondrial path way apoptosis Cell 201214859881000 152 Janikiewicz J Hanzelka K Kozinski K Kolczynska K Dobrzyn A Islet βcell failure type 2 diabeteswithin network toxic lipids Biochem Biophys Res Commun 20154603491496 153 Lupi R Dotta F Marselli L et al Prolonged exposure free fatty acids cytostatic proapoptotic effects human pancreatic islets evidence betacell death caspase mediated partially dependent ceramide pathway Bcl2 regulated Diabetes 200251514371442 154 Yano M Watanabe K Yamamoto T et al Mitochondrial dysfunction increased reactive oxygen species impair insulin secretion sphingomyelin synthase 1null mice J Biol Chem 20112865 39924002 155 Tong X Chaudhry Z Lee CC et al Cigarette smoke exposure impairs betacell function activation oxidative stress ceramide accumulation Mol Metab 202037100975 156 Kovilakath A Cowart LA Sphingolipid mediators myocardial 137 Smith U Pioglitazone mechanism action Int J Clin Pract Suppl pathology J Lipi Atheroscle 2020912349 20011211318 138 Murase K Odaka H Suzuki M Tayuki N Ikeda H Pioglitazone time dependently reduces tumour necrosis factoralpha level muscle improves metabolic abnormalities fatty rats Diabetologia 1998413257264 Wistar 139 Chaurasia B Tippetts TS Mayoral Monibas R et al Targeting cer amide double bond improves insulin resistance hepatic steatosis Science 20193656451386392 140 Apostolopoulou M Gordillo R Gancheva S et al Role ceramide todihydroceramide ratios insulin resistance nonalcoholic fatty liver disease humans BMJ Open Diabetes Res Care 20208 2e001860 141 Apostolopoulou M Gordillo R Koliaki C et al Specific hepatic sphingolipids relate insulin resistance oxidative stress inflammation nonalcoholic steatohepatitis Diabetes Care 2018 41612351243 142 Kolak M Westerbacka J Velagapudi VR et al Adipose tissue inflam mation increased ceramide content characterize subjects high liver fat content independent obesity Diabetes 2007568 19601968 143 Xia JY Holland WL Kusminski CM et al Targeted induction cer amide degradation leads improved systemic metabolism reduced hepatic steatosis Cell Metab 2015222266278 157 Canals D Perry DM Jenkins RW Hannun YA Drug targeting sphingolipid metabolism sphingomyelinases ceramidases Br J Pharmacol 20111634694712 158 Deng P Hoffman JB Petriello MC et al Dietary inulin decreases cir culating ceramides suppressing neutral sphingomyelinase expres sion activity mice J Lipid Res 20206114553 159 Simon J Ouro A AlaIbanibo L Presa N Delgado TC Martinez Chantar ML Sphingolipids nonalcoholic fatty liver disease hepatocellular carcinoma ceramide turnover Int J Mol Sci 201921 140 160 Buzzetti E Pinzani M Tsochatzis EA The multiplehit pathogenesis nonalcoholic fatty liver disease NAFLD Metabolism 201665 810381048 161 Masarone M Rosato V Dallio M et al Role oxidative stress pathophysiology nonalcoholic fatty liver disease Oxid Med Cell Longev 201820189547613 162 Lebeaupin C Vallée D Hazari Y Hetz C Chevet E Bailly Maitre B Endoplasmic reticulum stress signalling patho genesis nonalcoholic fatty liver disease J Hepatol 2018694 927947 163 Wandrer F Liebig S Marhenke S et al TNFreceptor1 inhibition reduces liver steatosis hepatocellular injury fibrosis NAFLD mice Cell Death Dis 2020113212 144 Prentki M Nolan CJ Islet beta cell failure type 2 diabetes J Clin 164 Niederreiter L Tilg H Cytokines fatty liver diseases Liver Invest 2006116718021812 Research 2018211420 145 Prentki M Peyot ML Masiello P Madiraju SRM Nutrientinduced metabolic stress adaptation detoxification toxicity pan creatic βcell Diabetes 2020693279290 146 Shimabukuro M Higa M Zhou YT Wang MY Newgard CB Unger RH Lipoapoptosis betacells obese prediabetic fafa rats Role serine palmitoyltransferase overexpression J Biol Chem 1998273493248732490 147 Boslem E Meikle PJ Biden TJ Roles ceramide sphingolipids Islets 201243 pancreatic βcell function dysfunction 177187 148 Lei X Bone RN Ali T et al Evidence contribution iPLA2beta islet apoptosis mediated betacell events 165 MendezSanchez N CruzRamon VC RamirezPerez OL Hwang JP BarrancoFragoso B CordovaGallardo J New aspects lipo toxicity nonalcoholic steatohepatitis Int J Mol Sci 2018197 2034 166 Di Sessa A Cirillo G Guarino S Marzuillo P Miraglia Del Giudice E Pediatric nonalcoholic fatty liver disease current perspectives diagnosis management Pediatric Health Med Ther 201910 8997 167 Mauer AS Hirsova P Maiers JL Shah VH Malhi H Inhibition sphingosine 1phosphate signaling ameliorates murine nonalcoholic steatohepatitis Am J Physiol Gastrointest Liver Physiol 20173123 G300G313 SINDHU ET AL 15 16 168 Raichur S Wang ST Chan PW et al CerS2 haploinsufficiency inhibits betaoxidation confers susceptibility dietinduced steatohepatitis insulin resistance Cell Metab 2014204 687695 169 Lee AY Lee JW Kim JE et al Dihydroceramide key metabolite regulates autophagy promotes fibrosis hepatic steatosis model Biochem Biophys Res Commun 2017494 34460469 170 Kasumov T Li L Li M et al Ceramide mediator nonalcoholic Fatty liver disease associated atherosclerosis PLoS One 2015 105e0126910 171 Chaurasia B Kaddai VA Lancaster GI et al Adipocyte ceramides regulate subcutaneous adipose browning inflammation metab olism Cell Metab 2016246820834 172 Sanyal AJ Pacana T A lipidomic readout disease progression dietinduced mouse model nonalcoholic fatty liver disease Trans Am Clin Climatol Assoc 2015126271288 173 Sajan MP Ivey RA Lee MC Farese RV Hepatic insulin resistance obob mice involves increases ceramide aPKC activity selec tive impairment Aktdependent FoxO1 phosphorylation J Lipid Res 20155617080 Ito M Suzuki J Tsujioka S et al Longitudinal analysis murine steatohepatitis model induced chronic exposure highfat diet Hepatol Res 20073715057 174 175 Jiang M Li C Liu Q Wang A Lei M Inhibiting ceramide synthesis attenuates hepatic steatosis fibrosis rats nonalcoholic fatty liver disease Front Endocrinol 201910665 176 Kurek K Piotrowska D Wiesiołek P et al Inhibition ceramide novo synthesis reduces liver lipid accumulation rats non alcoholic fatty liver disease Liver Intern Official J Intern Asso Stud Liv 201334 177 Taltavull N Ras R Marine S et al Protective effects fish oil prediabetes lipidomic analysis liver ceramides rats Food Funct 20167939813988 178 Lieber CS Leo MA Mak KM et al Model nonalcoholic steatohepatitis Am J Clin Nutr 2004793502509 188 Greco D Kotronen A Westerbacka J et al Gene expression human NAFLD Am J Physiol Gastrointest Liver Physiol 20082945 G1281G1287 189 Chiappini F Barrier A Saffroy R et al Exploration global gene expression human liver steatosis highdensity oligonucleotide microarray Lab Invest 2006862154165 190 Deevska G Sunkara M Karakashian C Peppers B Morris AJ NikolovaKarakashian MN Effect procysteine aging associated changes hepatic GSH SMase evidence tran scriptional regulation smpd3 J Lipid Res 2014551020412052 191 Griffin JH Fernandez JA Deguchi H Plasma lipoproteins hemosta sis thrombosis Thromb Haemost 2001861386394 192 Oörni K Posio P AlaKorpela M Jauhiainen M Kovanen PT Sphingomyelinase induces aggregation fusion small low density lipoprotein intermediatedensity lipoprotein particles increases retention human arterial proteoglycans Arterioscler Thromb Vasc Biol 200525816781683 193 Kinnunen PK Holopainen JM Sphingomyelinase activity LDL link atherosclerosis ceramide apoptosis Trends Cardiovasc Med 20021213742 194 Chatterjee SB Dey S Shi WY Thomas K Hutchins GM Accumula tion glycosphingolipids human atherosclerotic plaque unaf fected aorta tissues Glycobiology 1997715765 195 Levade T Auge N Veldman RJ Cuvillier O NegreSalvayre A Salvayre R Sphingolipid mediators cardiovascular cell biology pathology Circ Res 20018911957968 196 Martin SF Williams N Chatterjee S Lactosylceramide required apoptosis induced NSmase Glycoconj J 2006233147157 197 Mu H Wang X Wang H Lin P Yao Q Chen C Lactosylceramide promotes cell migration proliferation activation ERK12 human aortic smooth muscle cells Am J Physiol Heart Circ Physiol 20092971H400H408 198 Yang G Badeanlou L Bielawski J Roberts AJ Hannun YA Samad F Central role ceramide biosynthesis body weight regulation energy metabolism metabolic syndrome Am J Physiol Endocrinol Metab 20092971E211E224 179 Weyler J Verrijken A Hornemann T et al Association 1deoxysphingolipids steatosis steatohepatitis fibrosis nonalcoholic fatty liver disease Acta Diabetol 2021 583319327 199 Lallemand T Rouahi M Swiader A et al nSMase2 type 2neutral sphingomyelinase deficiency inhibition GW4869 reduces inflammation atherosclerosis apoe mice Arterioscler Thromb Vasc Biol 201838714791492 180 Zitomer NC Mitchell T Voss KA et al Ceramide synthase inhibition fumonisin B1 causes accumulation 1deoxysphinganine novel bases 1deoxydihydroceramides biosynthesized mammalian cell lines animals J Biol Chem 2009284847864795 1deoxysphingoid bioactive category 181 Penno A Reilly MM Houlden H et al Hereditary sensory neuropa thy type 1 caused accumulation neurotoxic sphingolipids J Biol Chem 2010285151117811187 182 Alecu I Othman A Penno A et al Cytotoxic 1deoxysphingolipids metabolized cytochrome P450dependent pathway J Lipid Res 20175816071 183 Bertea M Rutti MF Othman A et al Deoxysphingoid bases plasma markers diabetes mellitus Lipids Health Dis 2010984 184 Othman A Saely Plasma CH Muendlein 1deoxysphingolipids predictive biomarkers type 2 diabetes mellitus BMJ Open Diabetes Res Care 201531e000073 al A et 185 Gorden DL Myers DS Ivanova PT et al Biomarkers NAFLD pro gression lipidomics approach epidemic J Lipid Res 2015 563722736 186 Dohrn MF Othman A Hirshman SK et al Elevation plasma 1deoxysphingolipids type 2 diabetes mellitus susceptibility neuropathy Eur J Neurol 2015225806814 e855 InsaustiUrkia N SolsonaVilarrasa E GarciaRuiz C Fernandez Checa JC Sphingomyelinases liver diseases Biomolecules 2020 10111497 187 200 Park TS Hu Y Noh HL et al Ceramide cardiotoxin lipotoxic cardiomyopathy J Lipid Res 2008491021012112 201 Laaksonen R Ekroos K SysiAho M et al Plasma ceramides predict cardiovascular death patients stable coronary artery disease acute coronary syndromes LDLcholesterol Eur Heart J 2016372519671976 202 Carvalho LP Tan SH Ow GS et al Plasma ceramides prognos tic biomarkers arterial myocardial tissue correlates acute myocardial infarction JACC Basic Transl Sci 201832 163175 203 Dotson PP II Karakashian Alexander A NikolovaKarakashian MN Neutral sphingomyelinase2 redox sensitive enzyme role cat alytic cysteine residues regulation enzymatic activity changes oligomeric state Biochem J 20154653371382 204 Tellier E NegreSalvayre A Bocquet B et al Role furin tumor necrosis matrix metalloproteinasesphingolipid mitogenic pathway Mol Cell Biol 200727829973007 alphainduced activation factor 205 Philipp S Puchert M AdamKlages S et al The polycomb group pro tein EED couples TNF receptor 1 neutral sphingomyelinase Proc Natl Acad Sci U S A 2010107311121117 206 Adamy C Mulder P Khouzami L et al Neutral sphingomyelinase inhibition participates benefits Nacetylcysteine treatment postmyocardial infarction failing heart rats J Mol Cell Cardiol 2007433344353 16 16 SINDHU ET AL 207 Smith AR Visioli F Frei B Hagen TM Lipoic acid significantly agerelated decline vasomotion Br J rats restores Pharmacol 2008153816151622 208 Anderson HC Vesicles associated calcification matrix epiphyseal cartilage J Cell Biol 19694115972 209 EgeaJimenez AL Zimmermann P Lipids exosome biology Handb Exp Pharmacol 2020259309336 210 Akers JC Gonda D Kim R Carter BS Chen CC Biogenesis extra cellular vesicles EV exosomes microvesicles retroviruslike vesi cles apoptotic bodies J Neurooncol 20131131111 211 Engin A Darkside exosomes Adv Exp Med Biol 20211275 101131 212 Trajkovic K Hsu C Chiantia S et al Ceramide triggers budding exosome vesicles multivesicular endosomes Science 2008 319586712441247 213 Kowal J Tkach M Théry C Biogenesis secretion exosomes Curr Opin Cell Biol 201429116125 214 Llorente A Skotland T Sylvänne T et al Molecular lipidomics exosomes released PC3 prostate cancer cells Biochim Biophys Acta 20131831713021309 215 Kosaka N Iguchi H Yoshioka Y Takeshita F Matsuki Y Ochiya T Secretory mechanisms intercellular transfer microRNAs liv ing cells J Biol Chem 2010285231744217452 216 Singh R Pochampally R Watabe K Lu Z Mo YY Exosomemediated transfer miR10b promotes cell invasion breast cancer Mol Cancer 201413256 217 Sackmann V Sinha MS Sackmann C et al Inhibition nSMase2 reduces transfer oligomeric αsynuclein irrespective hyp oxia Fronti Molecu Neurosc 201912200 218 Bilousova T Simmons BJ Knapp RR et al Dual neutral sphingomyelinase2acetylcholinesterase inhibitors treatment Alzheimers disease ACS Chem Biol 202015616711684 219 Guo BB Bellingham SA Hill AF The neutral sphingomyelinase path way regulates packaging prion protein exosomes J Biol Chem 2015290634553467 220 Liu Y Wang Y Wang C et al Maternal obesity increases risk fetal cardiac dysfunction visceral adipose tissue derived exosomes Placenta 20211058593 221 Gu H Yang K Shen Z et al ER stressinduced adipocytes secrete aldoketo reductase 1B7containing exosomes cause non alcoholic steatohepatitis mice Free Radic Biol Med 2021163 220233 222 Kumar A Sundaram K Mu J et al Highfat dietinduced upregulation exosomal phosphatidylcholine contributes insulin resistance Nat Commun 2021121213 223 Li J Zhang Y Ye Y et al Pancreatic β cells control glucose homeo stasis secretion exosomal miR29 family J Extracel Ves 2021103e12055 224 Burillo J FernándezRhodes M Piquero M et al Human amylin aggregates release exosomes protective mechanism pancreatic β cells Pancreatic βhippocampal cell communication Biochimica et Biophysica Acta Mole Cell Res 186820215118971 225 Ying W Gao H Dos Reis FCG et al MiR690 exosomalderived miRNA M2polarized macrophages improves insulin sensitivity obese mice Cell Metab 2021 httpsdoiorg101016jcmet 202012019 How cite article Sindhu S Leung YH Arefanian H et al Neutral sphingomyelinase2 cardiometabolic diseases Obesity Reviews 202122e13248 httpsdoiorg 101111obr13248